48 results about "Colon tumors" patented technology

The invention discloses a lactococcus lactis subsp. lactis for regulating a signal path of colon tumor and an application thereof and belongs to the technical field of microorganisms. The lactococcuslactis subsp. lactis VM5 provided by the invention is preserved with the preservation number of GDMCC No.60256, is capable of enduring gastric acid and cholate, is capable of obviously relieving the inflammatory response of the colorectal part of a colorectal cancer model rat and is capable of reducing the tumor quantity on the colorectal parts of the model rat in the manner of regulating the expression of Notch1 signal path and VEGFR2 molecule in the colorectal tissue. Besides, the lactococcus lactis subsp. lactis VM5 is capable of improving the short chain fatty acid level in intestinal flora structures and intestinal tracts. The lactococcus lactis subsp. lactis VM5 is used for preparing the fermented food for restraining the happening of colorectal cancer and has a wide application prospect.

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.

Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM) was identified that selectively bound and was internalized into colon cancer cells. The peptide may be used to detect colon cancer cells and also may be used to selectively deliver therapeutic agents to the cells.

Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

The invention relates to use of ursolic acid as a colon tumor resistant medicament. The ursolic acid has the effects of inhibiting colon cancer / tumor cell proliferation and inducing apoptosis. In naked mouse in vivo experiments, the ursolic acid can effectively inhibit the proliferation of colon cancer transplanted tumor and inhibit the generation of tumor blood vessels, and has no obvious toxic or side effect on mice. The ursolic acid has the effect of inhibiting EGFR / MAPK signal channel phosphorylation of colon cancer cells, and the key target of the ursolic acid is to inhibit ERK1 / 2 protein phosphorylation. The ursolic acid which is synergetic with oxaliplatin serving as a clinical first-line chemotherapy medicament of the colon cancer has better curative effect. The ursolic acid has better proliferation inhibiting effect on the colon cancer cells of K-RAS gene mutation. The use of the ursolic acid as the colon tumor resistant medicament provides a new thought for treating the colon tumor.

The invention discloses an application of polygonatum polysaccharide in the preparation of drugs for assisting the inhibition of colon cancer. The polygonatum polysaccharide is preferably prepared through the following steps: adopting polygonatum sibiricum as the raw material, extracting the polygonatum sibiricum with boiling water, removing the proteins, carrying out dialysis, and finally carrying out an ethanol treatment so as to obtain the polygonatum polysaccharide. The polygonatum polysaccharide can modulate the tumor micro-environment by inhibiting the tumor from generating new vessels, carrying out immunity inhibition, carrying out anti-oxidation, inhibiting the growth of colon cancer fibroblast, and the like. Thus the polygonatum polysaccharide has a very good auxiliary effect on inhibiting the colon tumor.

Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.

The invention relates to a tumor vaccine, in particular to a process for prreparing an autogenous colon cancer vaccine. The invention resolves the problem that in the prior art, autologous DC and colon tumor antigen of a patient are employed to prepare the autogenous colon cancer vaccine, which is unfavorable in killing effect. Steps include that the DC is externally induced and cultivated, obtaining the mature DC, the autogenous colon cancer vaccine is taken as the tumor antigen for preparing, the prepared tumor antigen and the prepared DC are mixed and cultivated by 24 hours, thereby obtaining the DC modified by the autogenous colon cancer vaccine, and the DC and lymphocyte are mixed and cultivated according to the quantitative proportion of 1 to 10-1000. The kill rate of the final obtained autogenous colon cancer vaccine to colon cancer cells is remarkedly increased.

Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly colon cancer.

Certain cells, including cancer cells such as cells from colon tumors, are capable of expressing BCLP RNA. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP antibodies, peptides and small molecules provides a method of killing or inhibiting the growth of colon cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of colon tumors that express BCLP are described.

The invention discloses an application of polygonatum polysaccharide in the preparation of drugs for assisting the inhibition of colon cancer. The polygonatum polysaccharide is preferably prepared through the following steps: adopting polygonatum sibiricum as the raw material, extracting the polygonatum sibiricum with boiling water, removing the proteins, carrying out dialysis, and finally carrying out an ethanol treatment so as to obtain the polygonatum polysaccharide. The polygonatum polysaccharide can modulate the tumor micro-environment by inhibiting the tumor from generating new vessels, carrying out immunity inhibition, carrying out anti-oxidation, inhibiting the growth of colon cancer fibroblast, and the like. Thus the polygonatum polysaccharide has a very good auxiliary effect on inhibiting the colon tumor.

The present disclosure relates to a Fusobacterium nucleatum FomA protein vaccine, a preparation method and applications thereof. The preparation method comprises: linking a signal-peptide-sequence-deleted FomA gene linked to a MBP tag to an expression vector, transforming into Escherichia coli, carrying out induced expression, carrying out affinity purification on FomA recombinant protein by usingAmylose Resin High Flow, and carrying out enzyme digestion with a tev enzyme to remove the MBP tag to obtain the Fusobacterium nucleatum FomA protein vaccine. According to the present invention, theFusobacterium nucleatum FomA protein vaccine has good stability, and can effectively improve the immunity of organisms to Fusobacterium nucleatum, improve the survival rate and delay the occurrence and development of colons tumor; and in APCMin / + mice models, the FomA protein vaccine has significant protecting effect on the mice, can be used as a new colon tumor vaccine candidate, and has great application prospects.

The invention relates to a medical treatment instrument and discloses a colonic lumen series isolating membrane. The isolating membrane is tubular; a first annular airbag integrally connected with the isolatingmembrane is arranged at the lower end of the isolating membrane; a second annular airbag and a longitudinal airbag are arranged on the isolating membrane; the longitudinal airbag is communicated with the first annular airbag and the second annular airbag; a connecting part is arranged at the upper end of the isolating membrane. The tubular isolating membrane has isolation and protection effects on colonic anastomotic stoma in the colonic lumen; the contents (excrements) of the colonic lumen after operation move through an isolating membrane cavity, so that the excrements are prevented from being in contact with anastomotic stoma tissues, the anastomotic stoma is effectively protected from being polluted, the tension of the excrements in the colonic lumen on the anastomotic stoma is reduced, the healing of the anastomotic stoma is facilitated, and the occurrence of anastomotic fistula is reduced; the purpose of carrying out focal excision and anastomosisin the stage I under the circumstance that the bowel preparationis in no condition to be effectively performed for complete intestinal obstruction and the like caused by emergency treatment of left colon rupture or colon tumor due to war injury is achieved.

Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly colon cancer.

The invention relates to monoclonal antibody CAb--1 heavy and light chain variable region gene of human carcinoma of large intestine, the encoded polypeptides by the said genes, and the use of the genes and the polypeptides in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor, wherein a set of designed expanded primers are introduced. Based on the gene, gene engineering method can be employed to construct and express small molecular genetic engineering antibody of various forms, such as Fab antibody, chimeric antibody, and antibody fusion protein, which can be used in preparing medicament for diagnosis or treatment of large intestine (colon, rectum) cancers.

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.

The invention discloses a traditional Chinese medicine for treating susceptible intestinal obstruction after colon tumor operation. The traditional Chinese medicine is a medicament prepared from the following components in parts by weight: 5-15 parts of Chinese angelica, 10-20 parts of red paeony root, 5-15 parts of szechuan lovage rhizome, 10-20 parts of rehmannia glutinosa, 5-15 parts of peach seed, 3-10 parts of safflower, 5-15 parts of curcuma zedoary, 10-20 parts of immature bitter orange, 3-10 parts of costustoot, 3-10 parts of combined spicebush root, 3-10 parts of areca nut, 10-30 parts of astragalus membranaceus, 5-15 parts of largehead atractylodesrhizome and 10-30 parts of sargentgloryvine stem. A traditional Chinese medicine composition disclosed by the invention takes the effects of promoting blood circulation and removing stasis, promoting the circulation of qi and removing stagnation, removing swelling and relieving pain, and dredging the intestines as treatment principles, adopts qi tonifying medicaments such as Chinese angelica, astragalus membranaceus, red paeony root and the like in an auxiliary way, has a reasonable formula, is convenient to take, can be used for effectively treating intestinal obstruction, and especially can be used for treating intestinal obstruction caused by the colon tumor operation.

The invention relates to monoclonal antibody CAb--2 heavy and light chain variable region gene of human carcinoma of large intestine, the encoded polypeptides by the said genes, and the use of the genes and the polypeptides in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor. By introducing a set of designed expanded primers, a strain of monoclonal antibody Cab-2 heavy and light chain variable region gene of human carcinoma of large intestine is cloned from the hybrid tumor cells. The gene can be applied in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor.

The invention discloses application of gastrodia tuber polysaccharide in preparation of functional food with the effect of helping inhibit colon cancer. The gastrodia tuber polysaccharide is preferably prepared by the following method: extracting gastrodia tuber taken as a raw material with boiling water, removing protein, dialyzing and carrying out ethanol treatment. The gastrodia tuber polysaccharide has the function of adjusting the tumor microenvironment. The gastrodia tuber polysaccharide can adjust the tumor microenvironment through multiple ways such as inhabitation of tumor angiogenesis, activation of immunity and inhabitation of fibroblast growth of the colon cancer, so that the gastrodia tuber polysaccharide has a good effect of helping inhibit colon tumors.

Aminophosphinic acid derivatives were synthesized as potential inhibitors of renal dipeptidase, an enzyme overexpressed in benign and malignant colon tumors. Several compounds showed potent enzyme-inhibitory activity. These compounds can be used therapeutically and diagnostically for treatment and detection of tumors.

The invention provides a pharmaceutical composition for treating colon cancer and application thereof. The pharmaceutical composition for treating colon cancer consists of 2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazoline-4-yl)amino]-1H-pyrazole-5-yl}-N-(3-fluorophenyl) acetamide and 1,8-dihydroxy-3-carboxyanthraquinone. A compound group and a single drug group provided by the inventionboth have inhibitory effects on a colon cancer cell strain SW1116 in vivo, wherein the tumor inhibitory rate of the compound group is significantly different from that of the single drug group of 2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazoline-4-yl)amino]-1H-pyrazole-5-yl}-N-(3-fluorophenyl) acetamide or the single drug group of 1,8-dihydroxy-3-carboxyanthraquinone; and both groups play a significant synergistic role in inhibiting the proliferation of the colon cancer cell strain SW1116, in which the compound group can inhibit the growth of colon tumor, and the tumor inhibitory rate can reach up to 90.3%.

The invention discloses a traditional Chinese medicine for preventing postoperative recurrence of a colon tumor, and belongs to the technical field of the traditional Chinese medicine. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 8 parts of astragalus membranaceus, 4 parts of ginseng, 9 parts of Chinese yam, 6 parts of maltose, 6 parts of sea-buckthorn, 3 parts of lilium brownie, 5 parts of semen juglandis, 8 parts of pangolin, 6 parts of malt, 4 parts of poria cocos, 9 parts of angelica sinensis, 2 parts of fruit of Chinese wolfberry, 9 parts of rehmannia, 6 parts of black-bone chicken, 5 parts of euphoria longan, 8 parts of Chinese-date, and 3 parts of liquorice. The medicines are added with honey and water so as to be prepared into traditional Chinese medicine pills. The traditional Chinese medicine adopts pure natural Chinese herbal medicines which are free of toxic and side effects, so that recovery of a gastrointestinal system after a colon tumor surgery is facilitated; the traditional Chinese medicine for strengthening the spleen and stomach is added to assist; the medicines for relieving cancer or tumor symptoms with the effects of invigorating spleen and replenishing qi, enriching the blood and promoting blood circulation, promoting blood circulation to remove blood stasis and the like are combined, so as to achieve the effect of recovering and preventing the postoperative recurrence of tumors.

Disclosed are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells. Compositions and methods are further provided to assess markers of marker genes to predict outcome of treatment using proteasome inhibitors to patients having a solid tumor, such as a lung tumor or a colon tumor.

Provided are a method of predicting the onset and causative factors of colon tumors such as a colon polyp, colon cancer, and the like through metagenomic analysis of bacteria-derived extracellular vesicles present in a human body-derived substance, and a method of diagnosing causative factors and risk of colon tumors by sequencing of a metagenome present in bacteria-derived extracellular vesicles in stool or urine.